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Service: study protocol of a phase III fast-track
randomised controlled trial
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Caty Panell1, Elmien Brink7, Chiara De Biase1,7, Wei Gao1, Caroline Murphy8, Paul McCrone9, John Moxham3
and Irene J Higginson1
Abstract
Background: Breathlessness is a common and distressing symptom affecting many patients with advanced disease
both from malignant and non-malignant origin. A combination of pharmacological and non-pharmacological
measures is necessary to treat this symptom successfully. Breathlessness services in various compositions aim to
provide comprehensive care for patients and their carers by a multiprofessional team but their effectiveness and
cost-effectiveness have not yet been proven. The Breathlessness Support Service (BSS) is a newly created
multiprofessional and interdisciplinary outpatient service at a large university hospital in South East London. The
aim of this study is to develop and evaluate the effectiveness and cost effectiveness of this multidisciplinary
out–patient BSS for the palliation of breathlessness, in advanced malignant and non-malignant disease.
Methods: The BSS was modelled based on the results of qualitative and quantitative studies, and systematic
literature reviews. A randomised controlled fast track trial (RCT) comprising two groups: 1) intervention (immediate
access to BSS in addition to standard care); 2) control group (standard best practice and access to BSS after a
waiting time of six weeks). Patients are included if suffering from breathlessness on exertion or at rest due to
advanced disease such as cancer, chronic obstructive pulmonary disease (COPD), chronic heart failure (CHF),
interstitial lung disease (ILD) or motor neurone disease (MND) that is refractory to maximal optimised medical
management. Both quantitative and qualitative outcomes are assessed in face to-face interviews at baseline, after 6
and 12 weeks. The primary outcome is patients' improvement of mastery of breathlessness after six weeks assessed
on the Chronic Respiratory Disease Questionnaire (CRQ). Secondary outcomes for patients include breathlessness
severity, symptom burden, palliative care needs, service use, and respiratory measures (spirometry). For analyses, the
primary outcome, mastery of breathlessness after six weeks, will be analysed using ANCOVA. Selection of covariates
will depend on baseline differences between the groups. Analyses of secondary outcomes will include patients’
symptom burden other than breathlessness, physiological measures (lung function, six minute walk distance), and
caregiver burden.
(Continued on next page)
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Discussion: Breathlessness services aim to meet the needs of patients suffering from this complex and burdensome
symptom and their carers. The newly created BSS is different to other current services as it is run in close
collaboration of palliative medicine and respiratory medicine to optimise medical care of patients. It also involves
professionals from various medical, nursing, physiotherapy, occupational therapy and social work background.
Trial registration: ClinicalTrials.gov (NCT01165034)
Background
Breathlessness is a common, distressing symptom in
advanced malignant and non-malignant disease, causing
considerable disability for patients, and anxiety and so-
cial isolation for family and carers [1-3]. Breathlessness
is particularly prevalent and difficult to manage in the
late terminal stages of disease. Studies have shown that
94% of patients with chronic lung disease [4], 78% of
those with lung cancer [5] and more than 50% of
patients with heart disease [6] suffer from breathlessness
in the last year of life. Most studies examining the pro-
gression of breathlessness in cancer over time show
increased severity of breathlessness towards death [7,8].
The US SUPPORT study reported that around 70% of
COPD patients experienced moderate to severe breath-
lessness in the last six months of life, increasing to more
than 80% over the final 3 days [4]. As a result, breath-
lessness in end-stage disease is responsible for significant
healthcare resource usage with up to 60% hospital ad-
mission rates in patients presenting with breathlessness
to a cancer treatment centre [9].
Once treatment aimed at slowing progression of the
underlying disease has been optimised, palliation of
breathlessness usually involves a combination of
pharmacological (opioids, benzodiazepines, oxygen ther-
apy) and non-pharmacological (rollator devices, fan ther-
apy, breathing control) strategies but one single
intervention will probably not help sufficiently with
breathlessness [10]. Multidisciplinary rehabilitation pro-
grammes, incorporating exercise training and education,
have been shown to reduce breathlessness and improve
exercise capacity in COPD [11], heart failure [12], and
cancer [13]. However, patients with advanced disease are
often too ill to attend pulmonary rehabilitation pro-
grammes. In the 1990s, Corner et al developed and
tested a nursing clinic for lung cancer patients offering
breathing control, activity pacing, relaxation techniques,
and psychosocial support [14,15]. In a multi-centre RCT,
the intervention group had significantly less breathless-
ness, better performance status, and lower levels of de-
pression compared to best usual care [14]. Based on
these experiences, Booth et al developed a multiprofes-
sional Breathlessness Intervention Service (BIS) [16,17]
which is currently under evaluation following the MRC
framework for complex interventions [18]. The BIS is
offering specialist advice to manage breathlessness in
patients with disease of any aetiology. The accessibility
of breathlessness services is, however, not uniform
across the NHS. Difficulties with provision result, in
part, from a lack of evidence as to the most effective,
and cost-effective, organisational strategies.
We therefore designed a study to develop and evaluate
a new multiprofessional and interdisciplinary Breathless-
ness Support Service (BSS) in Southeast London for
people suffering from breathlessness due to advanced
disease and their families/carers. We present the proto-
col of the intervention and the trial to ensure independ-
ence of the results and to stimulate criticism and
suggestions from the journal readers.
Aims and objectives
The aim of this study is to develop and evaluate the ef-
fectiveness and cost effectiveness of a multidisciplinary
out–patient Breathlessness Support Service (BSS) for the
palliation of breathlessness, in advanced malignant and
non-malignant disease at King’s College Hospital London.
Objectives are:
1. To assess the effect of the BSS on patients’ mastery
of breathlessness and other breathlessness measures.
2. To assess the effect of the BSS on physiological
outcome measures.
3. To assess the effect of the BSS on caregiver burden.
4. To compare NHS resource usage and costs in the
two study arms.
5. To explore patients’ experiences using the BSS.
Methods/Design
Modelling and development of BSS
The BSS was designed following the Medical Research
Council (MRC) Guidance for the development and
evaluation of complex interventions [18,19]. This ap-
proach has been used to develop and evaluate a range of
services and interventions in palliative care [16,20]. This
phase III study builds on already completed pre-clinical/
theoretical (0), modelling (I) and exploratory (II) phases
which are described below.
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Phase 0: preclinical/ theoretical phase
The theoretical basis of the BSS was established by
reviewing published literature on the impact of breath-
lessness on healthcare usage in palliative care, and eva-
luations of breathlessness services that are already in
place. The magnitude of the reduction in healthcare re-
source usage by existing breathlessness advisory services
[21,22] and corroborative evidence from related rehabili-
tative and educational programmes [12,13] was also
sought. Evidence for the efficacy of pharmacological and
non-pharmacological palliation of breathlessness was
reviewed [13,23-25]. This allowed specification of the ac-
tive ingredients of the intervention, in terms of both the
personnel mix and management strategies that would be
offered in the service.
Phase I: modelling
We conducted qualitative interviews with over 80
patients with COPD, motor neuron disease, and cancer,
and their families and caregivers both in the clinical set-
ting (rehabilitation classes, out-patient clinics)[26-29],
and informally in patient groups such as the British
Lung Foundation Breathe Easy groups. Patients’, carers’
and healthcare professionals’ views on factors precipitat-
ing emergency health resource use, such as Accident
and Emergency visits were also sought. The issues raised
have focussed our intervention and include: need to pro-
vide educational and training material, need to have a
multi-professional approach, need to include an optional
home visit assessment, the need to have a plan of how
to deal with crises and need to include support for care-
givers. These patient interviews have helped to define
our target group, to better understand the relationships
between the proposed components of the breathlessness
service, and the potential for improved cost-effectiveness
of the service compared to best usual medical care. In
addition, we have consulted widely within the King’s
College Hospital Trust.
Setting
The BSS is provided as an outpatient clinic based in the
Cicely Saunders Institute at King’s College Hospital in
Southeast London. The hospital serves an estimated
population of 3.5 million people, and has approximately
1400 hospital admissions for breathlessness (=3700 bed
days) per year. The area has a network of palliative care
services including hospices, community services and
hospital support teams, co-ordinated through the South
London Palliative Care Network and other regionally
based networks.
Study design of phase III RCT
A randomised controlled fast track trial (RCT) compris-
ing two groups: 1) intervention (immediate access to
BSS in addition to standard care); 2) control group
(standard best practice and access to BSS after a waiting
time of six weeks). Consenting participants are randomly
allocated to one of the groups after baseline assessment.
The fast track design gives all patients the opportunity
to access the service. Patients will continue to have the
same access to specialist medical and palliative care ser-
vices as was available to them prior to entry into the
trial. This approach is based on a similar study design
developed by Higginson et al, to evaluate the effective-
ness of a new palliative care and neurology service for
patients severely affected by Multiple Sclerosis [20].
Inclusion criteria
Patients suffering from breathlessness on exertion or at
rest due to advanced disease such as cancer, chronic ob-
structive pulmonary disease (COPD), chronic heart fail-
ure (CHF), interstitial lung disease (ILD) or motor
neurone disease (MND). The underlying disease should
be optimally medically managed. Patients must be able
to engage with short term physiotherapy. If patients
are suffering from acute exacerbations, they are put on
a waiting list for two weeks and are then entered into
the trial.
Exclusion criteria
Patients with breathlessness of unknown cause, and
patients with a primary diagnosis of chronic hyperventi-
lation syndrome are excluded from study participation.
Patients are also excluded if they are too ill to come to
the clinic, and are unable to provide informed consent
either due to cognitive problems or to the severity of
their illness.
Intervention
The BSS is a multi-professional and interdisciplinary
service provided by two doctors, a clinical nurse spe-
cialist for lung cancer, a respiratory physiotherapist, an
occupational therapist, and a social worker. Doctors
come from a palliative medicine and a respiratory
medicine background.
Out-patient clinics take place once a week. Patients
are invited to come twice to the clinic within 4 weeks
and will also receive a home visit. Patients see 1-2 health
professionals per visit. Each patient is discussed by the
respiratory and palliative care professionals before the
patient is seen. The patient is reviewed by the respiratory
doctor first, who then hands over to the palliative care
professional after seeing the patient. Details of the ser-
vice are given in Table 1.
At the first meeting, patients receive an information
pack with five fact sheets on breathlessness, a breathless-
ness mantra, a relaxation CD, a hand-held fan, and in-
formation about cooling the face, e.g. with a small spray
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Table 1 Details of Breathlessness Support Service
Time Type of contact
with clinic
Content of meeting
Week 1 First outpatient
clinic visit
Contact with respiratory medicine
• explore the symptom of breathlessness and its triggers
• establish underlying cause of breathlessness
• optimise disease-orientated management
• review of previous investigations
Contact with palliative medicine
• experience of breathlessness
• development of crises plan
• burden on patient & family
• symptom burden (other than breathlessness)
• psychosocial & spiritual issues
• introduction of non-pharmacological measures such as rollator and hand-held fan
Week 2 – 3
Week 2 - 3
Home visit
Telephone call
Based on the patients’ needs as assessed during home visit:
Physiotherapy input
• review of the positions of breathlessness
• provision of a walking aid
• breathing control techniques and anxiety-panic cycle
• management of exacerbations in COPD
• home programme of exercise (DVD, personalised sheet)
• cough minimisation techniques
• pacing and fatigue management
• sputum clearance techniques
• ambulatory oxygen assessments
• referral to pulmonary rehabilitation
Occupational therapy input
• assessment of ADL (mobility / transfers, self care and domestic ADL)
• assessment for aids and minor adoptions and referral for provision of equipment
• wheelchair prescription
• education on planning, pacing and energy conservation techniques to patients and carers
• referral to other community services (local / out of area), as appropriate
• assessment of need for social support and liaison with the BSS social worker, as appropriate
• liaison with the BSS team regarding interventions and feedback
Social worker input
patient and or carer assessment including understanding of disease and symptoms &
information needs and coping strategies
Week 4 - 5 second clinic visit Contact with palliative medicine
• re-evaluation of breathlessness and other symptoms
• checking of interventions
• referral to medical and/or palliative care services if appropriate
• discharge from service
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bottle spraying fine mist. The fact sheets were de-
veloped by Sara Booth et al in Addenbrooke’s Hospital,
Cambridge (www.cuh.org.uk/addenbrookes/services/clin-
ical/breathlessness_intervention_service/patient_informa-
tion_ leaflets.html), containing information on breathless
ness: information and commonly asked questions; man-
aging breathlessness; handheld fan; positions to ease
breathlessness; a distraction technique: using the five
senses. If necessary, patients are also provided with infor-
mation more tailored to their specific needs.
The patients receive a letter after the clinic visits with
copies to the GPs and the referrers summarizing what
has been discussed and recommended.
After the first appointment in the clinic and initial
screening of patients’ needs, the physiotherapist (PT) in
liaison with the occupational therapist (OT) provides
support within three weeks of patient’s first attendance
at the clinic. After arranging a suitable time by telephone
either PT or OT visits the patients at home or a joint
home visit is considered, as necessary. OT and PT aim
to facilitate independence, safety and quality in daily ac-
tivities, using a client centred approach. The visits aim
to identify and modify domestic factors that may be
negatively impacting on breathlessness and create an
individualised functional programme. The therapists also
refer to other rehabilitation if appropriate.
Following their initial clinic visit each patient and/or
carer will be contacted via telephone by the BSS social
worker and assessed to see whether subsequent social
work involvement is indicated or referral to other sup-
portive services are required.
Control group
Patients randomised to the control group continue with
optimal medical management as prescribed by their
healthcare provider with the same access to generalist
(GP, district nurse) and specialist medical (respiratory,
cardiology, neurology) and palliative care services (com-
munity, hospital, hospice) as was available to them prior
to entry into the trial. After the final assessment (6-7
weeks), patients will be entered into the intervention
arm of the study (the BSS).
Recruitment procedure
Participants are recruited to the study by referral from
respiratory medicine, pulmonary rehabilitation, cardi-
ology, palliative care services, community services, and
GPs. The referring clinicians gain permission from
patients for their details to be passed to the study team.
The clinical research fellow (CRF), using a standard
protocol, screens referrals and sends a letter giving infor-
mation about the trial of the new service and an invita-
tion to participate, before telephoning patients several
days after receipt of the letter to agree consent. The CRF
then arranges an appointment for the baseline assess-
ment with the patient and, ideally, the carer. This first
appointment takes place in the patient’s home. At this
appointment, written informed consent for participation
in the study is obtained from participants.
Randomisation and blinding
Allocation to the intervention group (IG) or control
group is performed by the Clinical Trials Unit at King’s
College London, following the baseline interview, inde-
pendently of the research and clinical team. As the
group under study is heterogeneous with regard to some
key variables, minimisation was chosen as a method for
allocation in order to minimise the imbalance between
the treatment groups with respect to baseline character-
istics [30]. Factors considered are cancer versus non-
cancer, breathlessness severity (NRS >3), presence of an
informal caregiver and ethnicity (white versus other).
The BSS clinical administrator is informed about the al-
location via e-mail and sends appointment letters to
patients and arranges subsequent clinic appointments.
This allows the CRF and the research nurses to be blind
to which study arm patients have been assigned. Patients
are asked not to tell the CRF and research nurses to
which arm they were allocated.
Timing of data collection
Data is collected simultaneously in both groups, as sum-
marised in Figure 1. Baseline data (prior to randomisa-
tion) (t1) is collected in each patient’s home by the CRF.
This includes all questionnaires mentioned below and
physiological tests using a portable spirometer (Vitalo-
graph Gold StandardW,VitalographW Buckingham, UK).
Three to four weeks after the baseline assessment all
patients receive a telephone call from the CRF, during
which each patient completes the mastery section of the
CRQ (t2). Baseline assessment measures are repeated in
the patients home six to seven weeks after entry to the
study (t3). These data will be used for analysis of pri-
mary outcomes.
Subsequently, patients complete a second telephone
questionnaire as previously described between week nine
and ten of the study (t4). Finally baseline measures are
repeated between week 12 and 13 in all patients (t5), these
data will be used for analysis of secondary outcomes.
The timing of interventions and data collection has
been designed to allow for short disease trajectories in
patients with cancer and minimise patient burden, whilst
allowing time for interventions to have the desired ef-
fect. Four weeks is considered to be the minimum length
of pulmonary rehabilitation programmes that give a clin-
ically significant benefit [31]. Measures for each time
points are displayed in Table 2.
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Week
1
2
3
4                                                                   
5
6
7
8
9
10
11
12
Referred to the BSS
Ineligible
Not meeting inclusion criteria 
Declined to participate 
Home visit (end of intervention interview) (t3)
Breathlessness Support Service
1st clinic visit
PT / OT HV
Standard care (control)
Home visit (consent, baseline assessment & data entry) (t1)
Randomisation (using minimisation method)
Home visit (control group receives the BSS) (t3)
Breathlessness Support Service
1st clinic visit
PT / OT HV
Home visit (end of intervention interview) (t5)Home visit (follow up interview) (t5)
TC (t2)TC (t2)
TC (t4)TC (t4)
Figure 1 Flow diagram of patients through the study.
Table 2 Measures for each time point
Baseline 4 weeks
(telephone)
6 weeks 8 weeks
(telephone)
12 weeks
Chronic Respiratory Disease Questionnaire (CRQ) x x x x x
NRS breathlessness x x x
Dyspnoea 12 x x x
Palliative Care Outcome Scale (POS) x x x
POS Symptom Scale (POS-S) x x x
London Chest Activity of Daily Living Scale (LCADL) x x x
Hospital Anxiety and Depression Scale (HADS) x x x
EuroQol (EQ-5D) x x x
Zarit Burden Inventory x x x
Client Service Receipt Inventory (CSRI) x x x
Spirometry x x x
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Outcome measures
Both quantitative and qualitative outcomes are assessed.
Baseline data includes age, sex, clinical diagnosis, height,
weight and smoking history. Data are collected from
participants by face-to-face interviews at two time-
points and telephone interviews.
Primary outcome measure
The primary outcome is improvement of mastery of
breathlessness after 6 weeks, as assessed by a change in
the score in the Mastery domain of the Chronic Respira-
tory Disease Questionnaire (CRQ) [32]. Questions
within this domain relate to breathlessness. The CRQ is
a multidimensional tool, and is one of the most widely
used measures of quality of life (QOL) in chronic re-
spiratory disease. The CRQ is an interview administered
questionnaire, but a self-administered version maintains
validity and responsiveness [33].
Secondary outcome measure
Breathlessness A Numerical Rating Scale (NRS) [34] is
used as secondary outcome measure to assess the inten-
sity of the sensation of breathlessness on average, at
worst, at rest and on exertion over the last 24 hours.
The NRS correlates highly with the visual analogue dys-
pnoea scale [34], and has the advantage of being able to
be used during the telephone assessments. In addition,
we included the Dyspnoea 12, a newly validated measure
which provides a global score of breathlessness severity
that incorporates both “physical” and “affective” aspects,
and can measure dyspnoea in a variety of diseases [35].
Symptom-related QOL The Palliative care Outcome
Scale (POS) and POS-symptoms are used to assess and
quantify palliative care symptoms in addition to breath-
lessness [36]. The London Chest Activity of Daily Living
Scale (LCADL) is used to assess the impact of the ser-
vice on activities of daily living. The LCADL has been
used as an outcome measure in COPD, and has been
shown to be valid, reliable and responsive to change
[37]. The Hospital Anxiety and Depression Score is
used to screen patients for anxiety and depression [38],
and the EQ-5D [39] is used as a generic health-related
QOL measure. EQ-5D is a standardised instrument for
use as a measure of health outcome and is especially
suited to cost-effectiveness analyses as it can be used to
generate quality-adjusted life years (QALYs). It is applic-
able to a wide range of health conditions and treat-
ments, and provides a simple descriptive profile and a
single index value for health status. Carer burden is
assessed using the Zarit Burden Inventory [40].
Service use Contacts with the BSS are recorded cen-
trally. The Client Service Receipt Inventory (CSRI) is
used to record other service use in the three-month
period prior to baseline assessment and then for each
follow-up period. The CSRI has been used in over 200
studies to assess costs and takes approximately 20 min-
utes to complete. Services included will be health care
(primary and secondary), medication, social care and in-
formal care from family/friends. The CSRI has not previ-
ously been used specifically in a breathless population,
therefore we adapted the CSRI for this study. Lost work
time for patients and carers will be recorded.
Physiological measures These include spirometry
(forced expiratory volume in 1s [FEV1], slow vital cap-
acity [VC], peak expiratory flow rate [PEF]), performed
in accordance with the American Thoracic Society
guidelines [41]. The highest value for FEV1, VC and PEF
from three reproducible efforts will be recorded and
compared to predicted normal values [41]. Pulse oxim-
etry is measured at rest and during the six minute walk
test [42] in all participants.
When attending the clinic, patients are asked to per-
form a six minute walk test as a field test of exercise
capacity. The distance walked (6 minute walk distance,
[6MWD]) has demonstrated strong correlation with
peak rate of oxygen uptake, maximum work rate [43]
and prognosis in patients with lung cancer [44] and
chronic respiratory disease [45].
Patients experience with the BSS A subsample of
patients will be interviewed using semi structured in–
depth interviews to understand how the intervention
might work and what positive and negative aspects
patients experienced. Patients will be identified using a
sampling frame (see Table 3). The interviews will follow
a topic guide which includes questions on patients’ ex-
perience and views regarding service provision, location
of the service, help and information received, and impact
of service. The interviewer will have had no previous
contact with the patient during the BSS contact. Inter-
views will take place at the end of the 12 weeks period
when patients have attended the BSS.
Sample size calculation
There are limited data to provide estimates for a sample
size calculation and this study will inform calculations
for the future. Based on the primary outcome, the mas-
tery domain on the CRQ [32]to detect a mean difference
of 0.70 on this 7 point scale with a standard deviation of
1 [46], and at 5% significance level, power of 80% we
would require at least 33 patients in each group. Due to
the advanced stage of illness in the patients we esti-
mate an attrition rate of 40% which means that we
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would aim to recruit at least 110 patients, which over
12 months, would be 9-10 patients per month. With
over 1,000 admissions for breathlessness per year, this
should be achieved.
Analysis
First, we aim to understand missing data in the study
and proportions and reasons for drop out. Second, we
will compare baseline data between the intervention and
the control group using parametric and non-parametric
tests as appropriate. Third, the primary outcome, mas-
tery of breathlessness after six weeks, will be analysed
using a t-test if there are no differences between groups
or ANCOVA with selection of co-variates depending on
baseline differences between the groups. Analyses of sec-
ondary outcomes will include patients’ symptom burden
other than breathlessness, physiological measures, and
caregiver burden.
Dealing with missing data will include various impu-
tation methods. The alpha level for all statistical analyses
will be set at two-sided 0.05. All analyses will be per-
formed using SPSS software.
Qualitative interviews will be tape-recorded, tran-
scribed verbatim and analysed using content analysis.
NVivo is used to facilitate qualitative analyses.
Economic evaluation
The service use data recorded with the CSRI will be
combined with appropriate unit cost information (for
example the annual compendium produced by the Per-
sonal Social Services Research Unit at the University of
Kent). The costs of the BSS itself will be estimated using
local accounting data and information on activity rates.
Informal care costs will be estimated using the unit cost
of a homecare worker. Lost employment will be costed
using average wage rates. Cost data are generally skewed
and therefore to make comparisons between the groups
bootstrapping methods will be used. Cost-effectiveness
will be assessed by combining the data on costs with the
data on the mastery domain of the CRQ. Cost-utility
estimates will be made using QALYs generated from the
EQ-5D. If costs are higher and outcomes better for the
BSS then incremental cost-effectiveness ratios will be
generated which will indicate the extra cost incurred to
achieve an extra unit of outcome. Uncertainty around
cost-effectiveness and cost-utility estimates will be
explored by resampling from the dataset using boot-
strapping, calculating cost and outcome differences for
each resample and plotting these on cost-effectiveness
planes. Cost-effectiveness acceptability curves will be
used to show the probability that the BSS is more cost-
effective than usual care for a range of values placed on
a unit improvement in outcome.
Project advisory group
A multidisciplinary project advisory group (PAG) has
been established for the duration of the study. The PAG
includes clinicians and researchers, and others working
with breathless patients. The specialities of respiratory
medicine and palliative medicine are represented on the
PAG, as are local services that linked with the new
breathlessness support service. A patient and carer rep-
resentative are also PAG members. The PAG meets
regularly and also make contact by e-mail and telephone
with the project team.
Ethics approval
Ethics approval for the study was gained from the King’s
College Hospital ethics committee (Ref. 10/H0808/17).
The study meets the requirements of the local Research
Governance Framework. The study protocol is registered
with ClinicalTrials.gov (NCT01165034).
Discussion
The complexity of breathlessness, the needs of patients
with advanced disease living with this distressing symp-
tom, and the burden of their carers demand a combination
of various pharmacological and non-pharmacological
interventions. To provide these, various types of breath-
lessness services have been developed over the last years
but their effectiveness and especially cost-effectiveness
remains to be shown.
The BSS introduced here was developed following the
MRC framework for complex interventions. Building on
previous own research [13,26-28,47] and experiences
Table 3 Sampling frame for qualitative interviews
Cancer Non-cancer (COPD/ CHF/ILD etc.)
Severity of breathlessness
NRS< 3 4 – 6 4 – 6
NRS≥ 3 4 – 6 4 – 6
Sex
male 4 – 6 4 – 6
female 4 – 6 4 – 6
Age
< 50 years 2 – 3 2 – 3
50 – 65 years 2 – 3 2 – 3
≥ 65 years 2 – 3 2 – 3
Caregiver situation
living with caregiver 4 – 6 4 – 6
no caregiver 4 – 6 4 – 6
Intervention
Fast-track 4 – 6 4 – 6
Waiting list 4 – 6 4 – 6
Total 10 10
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from colleagues in Cambridge [16,17,48] we modelled
our service to fit the needs of an ethnically diverse popu-
lation in South East London. Although there are some
similarities to the BIS in Cambridge such as multi-
professional support, service for cancer and non-cancer
patients, and short-term intervention with consecutive
discharge of patients, there are also some pronounced
differences. We recognised the need to introduce re-
spiratory expertise in such a service and therefore run,
for the first time, an interdisciplinary breathlessness ser-
vice with colleagues from palliative medicine and re-
spiratory medicine. This allows us to provide special
expertise to optimise treatment of the underlying disease
but also to include physiological measures in the assess-
ment of patients and the evaluation of the service such
as lung function and exercise capacity to better describe
the sample and to understand the potential effects of the
interventions provided. The composition of professionals
being involved in the service has been extended in com-
parison to other services and includes the expertise of a
nurse, an occupational therapist and a social worker. In
contrast to the Cambridge Service with provision of the
BIS mainly in patients’ homes [49] is the predominant
provision of the BSS as an outpatient clinic with one
home visit by the physiotherapist or the occupational
therapist between two clinic visits.
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